Therefore, cancer cells overexpressing A3A augment anti-tumor immune response might by secreting CCL5 and CXCL10 to recruit and activate CD8+ T cells in ESCC, which warrants further functional investigations. This evidence concerns the gene CXCL10 and cancer.